Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 571 to 580 of 624 total matches.
In Brief: New Benzodiazepine Warnings
The Medical Letter on Drugs and Therapeutics • Nov 02, 2020 (Issue 1610)
and physical dependence.1 Benzodiazepine
labels have contained a boxed warning about a risk of
serious drug ...
The FDA now requires boxed warnings in the package
inserts of benzodiazepines describing the potential for
these drugs to be abused and misused and to cause
addiction and physical dependence. Benzodiazepine
labels have contained a boxed warning about a risk of
serious drug interactions with opioids since 2016.
In Brief: A New Prostate Cancer Indication for Darolutamide (Nubeqa) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 19, 2023 (Issue 1679)
of nonmetastatic castration-resistant
prostate cancer (nmCRPC).1
MECHANISM OF ACTION — Androgen receptors ...
The androgen receptor inhibitor darolutamide
(Nubeqa – Bayer) has been approved by the FDA
for use in combination with docetaxel for treatment
of metastatic hormone-sensitive prostate cancer
(mHSPC). The drug was previously approved for
treatment of nonmetastatic castration-resistant
prostate cancer (nmCRPC).
Med Lett Drugs Ther. 2023 Jun 19;65(1679):e108 doi:10.58347/tml.2023.1679h | Show Introduction Hide Introduction
In Brief: Melphalan (Hepzato) for Uveal Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
duration of
response was 14 months.1 ADVERSE EFFECTS — In the FOCUS trial, cytopenias,
fatigue, nausea ...
...
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e148 doi:10.58347/tml.2023.1684d | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Postmenopausal Osteoporosis (online only)
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024 (Issue 1706)
fever, myalgia,
arthralgia) with oral formulations
and within 1-3 days of
infusion, most frequently ...
View the Comparison Table: Some Drugs for Postmenopausal Osteoporosis
Med Lett Drugs Ther. 2024 Jul 8;66(1706):e112-4 doi:10.58347/tml.2024.1706b | Show Introduction Hide Introduction
Xanomeline/Trospium (Cobenfy) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
greater with xanomeline/trospium than
with placebo in EMERGENT-2, but not in EMERGENT-3.1,2
Interim data ...
The FDA has approved Cobenfy (BMS), an oral
fixed-dose combination of the muscarinic agonist
xanomeline and the peripheral muscarinic antagonist
trospium chloride, for treatment of schizophrenia in
adults. It is the first antipsychotic drug to be approved
in the US for treatment of schizophrenia that does not
block dopamine receptors. This is the first approval
for xanomeline; trospium has been available for many
years for treatment of overactive bladder.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):177-9 doi:10.58347/tml.2024.1715a | Show Introduction Hide Introduction
Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
) Inhibitors
Adalimumab3 – Humira
(Abbvie)
10 mg/0.1 mL, 10 mg/
0.2 mL, 20 mg/0.2 mL,
20 mg/0.4 mL ...
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Datopotamab Deruxtecan (Datroway) for Advanced Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025 (Issue 1723)
4 and 6
(CDK4/6) inhibitor such as palbociclib (Ibrance).1,2
MECHANISM OF ACTION — Datroway ...
The FDA has approved datopotamab deruxtecan
(Datroway – Daiichi Sankyo/AstraZeneca), a trophoblast
cell-surface antigen-2 (Trop-2)-directed antibody
and topoisomerase inhibitor conjugate, for treatment
of adults with unresectable or metastatic hormone
receptor (HR)-positive, human epidermal growth factor
receptor 2 (HER2)-negative breast cancer who received
prior endocrine-based therapy and chemotherapy for
unresectable or metastatic disease.
Med Lett Drugs Ther. 2025 Mar 3;67(1723):e41-2 doi:10.58347/tml.2025.1723e | Show Introduction Hide Introduction
Upadacitinib (Rinvoq) for Giant Cell Arteritis
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025 (Issue 1733)
,
ulcerative colitis, and Crohn’s disease.1-4
THE DISORDER — Giant cell arteritis is a systemic
large-vessel ...
The oral Janus kinase (JAK) inhibitor upadacitinib
(Rinvoq – Abbvie) has been approved by the FDA
for treatment of giant cell arteritis. Upadacitinib
was approved earlier for treatment of rheumatoid
arthritis, psoriatic arthritis, ankylosing spondylitis,
nonradiographic axial spondyloarthritis, atopic dermatitis,
ulcerative colitis, and Crohn's disease.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):114-5 doi:10.58347/tml.2025.1733b | Show Introduction Hide Introduction
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
have been reported,
particularly after >1 month of use
Hyperalgesia, worsening pain that cannot be overcome ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
In Brief: Suspension of Johnson & Johnson COVID-19 Vaccine Lifted (online only)
The Medical Letter on Drugs and Therapeutics • May 17, 2021 (Issue 1624)
million doses of the single-dose vaccine had been
administered in the US at the time of the review.1-4 ...
On April 23, 2021, on advice from the Advisory
Committee on Immunization Practices (ACIP), the
FDA and CDC recommended that use of the Johnson
& Johnson adenovirus-based COVID-19 vaccine
resume despite its association with development of
thrombosis with thrombocytopenia syndrome (TTS).
Administration of the vaccine had been paused on April
13 because of 6 reports of TTS, but after completing a
data review that identified a further 9 cases associated
with the formulation, the agencies concluded that the
benefits of the vaccine outweighed its risks. About
7.98 million doses of the...